Logo image of TKNO

ALPHA TEKNOVA INC (TKNO) Stock Fundamental Analysis

NASDAQ:TKNO - Nasdaq - US02080L1026 - Common Stock - Currency: USD

5.28  -0.28 (-5.04%)

Fundamental Rating

3

Overall TKNO gets a fundamental rating of 3 out of 10. We evaluated TKNO against 55 industry peers in the Life Sciences Tools & Services industry. The financial health of TKNO is average, but there are quite some concerns on its profitability. TKNO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

TKNO had negative earnings in the past year.
TKNO had a negative operating cash flow in the past year.
TKNO had negative earnings in 4 of the past 5 years.
TKNO had negative operating cash flow in 4 of the past 5 years.
TKNO Yearly Net Income VS EBIT VS OCF VS FCFTKNO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

TKNO has a Return On Assets of -20.43%. This is in the lower half of the industry: TKNO underperforms 61.82% of its industry peers.
TKNO has a Return On Equity (-29.63%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -20.43%
ROE -29.63%
ROIC N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
TKNO Yearly ROA, ROE, ROICTKNO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

TKNO has a Gross Margin of 20.99%. This is amonst the worse of the industry: TKNO underperforms 80.00% of its industry peers.
In the last couple of years the Gross Margin of TKNO has declined.
The Profit Margin and Operating Margin are not available for TKNO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.99%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
TKNO Yearly Profit, Operating, Gross MarginsTKNO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 50 -50 -100

5

2. Health

2.1 Basic Checks

TKNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
TKNO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for TKNO has been increased compared to 5 years ago.
Compared to 1 year ago, TKNO has a worse debt to assets ratio.
TKNO Yearly Shares OutstandingTKNO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
TKNO Yearly Total Debt VS Total AssetsTKNO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TKNO has an Altman-Z score of 3.54. This indicates that TKNO is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.54, TKNO is doing good in the industry, outperforming 74.55% of the companies in the same industry.
A Debt/Equity ratio of 0.17 indicates that TKNO is not too dependend on debt financing.
TKNO has a Debt to Equity ratio of 0.17. This is comparable to the rest of the industry: TKNO outperforms 60.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z 3.54
ROIC/WACCN/A
WACC10.34%
TKNO Yearly LT Debt VS Equity VS FCFTKNO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TKNO has a Current Ratio of 5.64. This indicates that TKNO is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.64, TKNO is in the better half of the industry, outperforming 78.18% of the companies in the same industry.
A Quick Ratio of 4.71 indicates that TKNO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.71, TKNO is in the better half of the industry, outperforming 76.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.71
TKNO Yearly Current Assets VS Current LiabilitesTKNO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

5

3. Growth

3.1 Past

TKNO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 48.39%, which is quite impressive.
The Revenue has been growing slightly by 3.78% in the past year.
The Revenue has been growing by 12.68% on average over the past years. This is quite good.
EPS 1Y (TTM)48.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
Revenue 1Y (TTM)3.78%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%5.44%

3.2 Future

The Earnings Per Share is expected to grow by 17.00% on average over the next years. This is quite good.
The Revenue is expected to grow by 16.60% on average over the next years. This is quite good.
EPS Next Y31.28%
EPS Next 2Y17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year8.12%
Revenue Next 2Y12.25%
Revenue Next 3YN/A
Revenue Next 5Y16.6%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TKNO Yearly Revenue VS EstimatesTKNO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2028 2029 2030 20M 40M 60M 80M 100M
TKNO Yearly EPS VS EstimatesTKNO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.5 -1 -1.5

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TKNO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TKNO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TKNO Price Earnings VS Forward Price EarningsTKNO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TKNO Per share dataTKNO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

A more expensive valuation may be justified as TKNO's earnings are expected to grow with 17.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

TKNO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALPHA TEKNOVA INC

NASDAQ:TKNO (6/23/2025, 8:00:01 PM)

5.28

-0.28 (-5.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)N/A N/A
Inst Owners11.59%
Inst Owner Change-3.61%
Ins Owners9.19%
Ins Owner Change0%
Market Cap282.16M
Analysts80
Price Target11.22 (112.5%)
Short Float %26.91%
Short Ratio7.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.71%
Min EPS beat(2)10.13%
Max EPS beat(2)17.28%
EPS beat(4)3
Avg EPS beat(4)4.57%
Min EPS beat(4)-30.72%
Max EPS beat(4)21.57%
EPS beat(8)6
Avg EPS beat(8)9.14%
EPS beat(12)8
Avg EPS beat(12)-9.36%
EPS beat(16)11
Avg EPS beat(16)-14.17%
Revenue beat(2)2
Avg Revenue beat(2)3.35%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.18%
Revenue beat(4)3
Avg Revenue beat(4)2.12%
Min Revenue beat(4)-0.39%
Max Revenue beat(4)4.18%
Revenue beat(8)5
Avg Revenue beat(8)3.02%
Revenue beat(12)9
Avg Revenue beat(12)4.71%
Revenue beat(16)13
Avg Revenue beat(16)6.55%
PT rev (1m)0%
PT rev (3m)3.12%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.63%
EPS NY rev (3m)-1.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-4.47%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.52%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.38
P/FCF N/A
P/OCF N/A
P/B 3.59
P/tB 4.29
EV/EBITDA N/A
EPS(TTM)-0.48
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0.72
BVpS1.47
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.43%
ROE -29.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.99%
FCFM N/A
ROA(3y)-27.43%
ROA(5y)-17.44%
ROE(3y)-40.28%
ROE(5y)-25.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.25%
GM growth 5Y-14.67%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.69%
Cap/Sales 3.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.64
Quick Ratio 4.71
Altman-Z 3.54
F-Score4
WACC10.34%
ROIC/WACCN/A
Cap/Depr(3y)348.43%
Cap/Depr(5y)400.74%
Cap/Sales(3y)30.86%
Cap/Sales(5y)32.79%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55%
EPS Next Y31.28%
EPS Next 2Y17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.78%
Revenue growth 3Y0.77%
Revenue growth 5Y12.68%
Sales Q2Q%5.44%
Revenue Next Year8.12%
Revenue Next 2Y12.25%
Revenue Next 3YN/A
Revenue Next 5Y16.6%
EBIT growth 1Y23.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.57%
EBIT Next 3YN/A
EBIT Next 5Y17.51%
FCF growth 1Y80.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y66.75%
OCF growth 3YN/A
OCF growth 5YN/A